Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Luo ilmainen tunnus

Generic Sweden

40,30 SEK

0,00%

Alle 1K seuraajaa

GENI

First North Stockholm

IT Services

Technology

0,00 %
+10,71 %
+3,60 %
−13,15 %
−11,62 %
−31,93 %
−6,06 %
−26,33 %
+70,08 %

Generic Sweden operates in the IT sector. The company offers a platform for digital communication services that are integrated into customers' internal or external communication flows. The services are provided through a CPaaS model (Communication Platform as a Service). The company's customers are found in several sectors with a particular position in alarms and security, healthcare and e-health, and e-commerce. The company was founded in 1993 and is headquartered in Stockholm.

Lue lisää
Markkina-arvo
495,37 milj. SEK
Vaihto
1,07 milj. SEK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Liikevaihto ja EBIT-%

Liikevaihto milj.

EBIT-% (oik.)

EPS ja Osinko

EPS (oik.)

Osinko %

Pörssikalenteri
20.8.
2026

Osavuosikatsaus Q2'26

12.11.
2026

Osavuosikatsaus Q3'26

11.2.
2027

Vuosikatsaus '26

Kolmannen osapuolen analyysi

Generic: Broadening verticals lift the mix - ABG

* Volume growth in coming quarters * Growing verticals will likely add some costs * EV/EBIT of 10x '26e and 9x '27e Likely past the bottom of the cycle Volumes came in above our expectations. The Messaging segment (SMS, RCS, SenderID), Generic's largest...

Kolmannen osapuolen analyysi

Generic: Volumes back in business - ABG

* Volumes stronger than expected * Gross margin continues to be steady at ~44% * DOCS now penetrated >30% of municipalities Q1'26 details Generic reported Q1'26 sales of SEK 49m, 9% y-o-y growth (+6% vs ABGSCe 46m), driven by higher volumes in the SMS...

Kolmannen osapuolen analyysi

Generic: Bottoming before the bounce - ABG

* Volumes likely soft in Q1 * Management changes to weigh on earnings * EV/EBIT of 10-9x on '26e-'27e, ~60% below its CPaaS peers Likely at the bottom of the cycle The market continues to be weighed by pricing pressure and customers holding back on spending...

Liity Inderesin yhteisöön

Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.

FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Luo ilmainen tunnus
Kolmannen osapuolen analyysi

Generic: The gross margin story remains strong - ABG

* Sales up 3% y-o-y, held back by soft volumes and tough comps * We keep sales flat, and slightly raise opex * Trading at 9-8x on '26e-'27e EV/EBITA, below its historical median Recruiting and consulting costs weighing on EBIT Generic reported an in-...

Kolmannen osapuolen analyysi

Generic: Gross margins up but costs weigh in Q4 - ABG

* Sales -1% and adj. EBITA -5% vs ABGSCe * Gross profit of SEK 21.5m, up 5% y-o-y, and GM of 44% * SaaS continues to grow, DOCS adoption >26% of municipalities Q4'25 details Generic reports Q4'25 sales of SEK 49.2m (-1% vs ABGSCe 49.7m), broadly in line...

Kolmannen osapuolen analyysi

Generic: Margins over volumes - ABG

* Q4 growth partly offset by SMS volumes * Raising EBITA by 7-6% for '26e-'27e * 11-9x EV/EBITA on '26e-'27e, ~20% below historical median Softer quarter due to volumes Generic reports its Q4'25 on 12 February, and we expect sales of SEK 50m, representing...

Kolmannen osapuolen analyysi

Generic: Scaling efficiently for margin improvement - ABG

* Continued margin expansion driven by DOCS* EBIT estimates raised by 2-3% for '26e-'27e on scaling potential* Trading at 13x EV/EBIT, ~20% below its historical medianGrowing SaaS contributionGeneric reported a slightly better Q3, with sales of SEK 45m...

Kolmannen osapuolen analyysi

Generic: Margin expansion driven by SaaS - ABG

* Sales +3% and adj. EBITA +14% vs ABGSCe* DOCS adoption >24% of municipalities* Consensus adj. EBIT likely up mid single-digits Q3'25 details Generic reports Q3'25 sales of SEK 45m (+3% vs. ABGSCe 44m), supported by new contracts and an improved product...

Kolmannen osapuolen analyysi

Generic: Margin stability in a softer market - ABG

* Seasonally weaker volumes to weigh on earnings* 10-12% '26e-'27e sales growth, 21-22% EBIT margin* Trading at 12x EV/EBITA in '26e, ~15% below historical medianExpect usual seasonal impact on Q3 numbersGeneric reports its Q3'25 on 12 November, and ...

Kolmannen osapuolen analyysi

Generic: Communication flows, margin grows - ABG

* Gross margin at 45% (40%)* SaaS supports margins and outlook* Trading at ~11-9x EV/EBITA for '26e-'27eStrong margin improvementGeneric reported sales of SEK 44m, up 2% y-o-y (4% below ABGSCe), driven by: i) lower volume-based products (e.g. SMS), which...

Kolmannen osapuolen analyysi

Generic: Margins holding up well - ABG

* Sales -4% and adj. EBIT -11% vs ABGSCe* DOCS adoption >23% of municipalities* Consensus adj. EBIT likely down by mid single-digitsQ2'25 detailsGeneric reports Q2'25 sales of SEK 44.3m (-4% vs ABGSCe 46.2m), impacted by mix effects and smaller-sized...

Kolmannen osapuolen analyysi

Generic: Scalability on show - ABG

6% organic sales growth y-o-y SaaS momentum drives gross margin uplift... ... and leads to impressive EBIT growth of 41% y-o-y Q1: Sales growth of 6%, EBIT margin of 21.7% (16.3%) The Q1 report really showed the scalability of Generic's business model...

Kolmannen osapuolen analyysi

Generic: Ends 2024 in style - ABG

24% organic sales growth y-o-y Improved gross margin due to pricing and mix Opex flat y-o-y leads to 48% EBIT growth Q4: Sales growth of 24%, EBIT margin of 22.7% (19.0%) Generic continued its impressive comeback in Q4, where H1'24 profitability issues...

Kolmannen osapuolen analyysi

Generic: Strong quarter and outlook - ABG

24% organic sales growth y-o-y Improved gross margin due to price adjustments Opex growth to abate in the coming quarters Q3: Sales growth of 24%, EBIT margin of 20.6% (22.6%) In our view, Generic's Q3 results were impressive. Sales growth remained strong...

Kolmannen osapuolen analyysi

Generic: Strong growth, temporarily lower profitability - ABG

26% organic sales growth y-o-y Growth initiatives hurt profitability mid-term Pricing to act as a tailwind for gross margin in Q3 Q2: Sales growth of 26%, EBIT margin of 15.5% (20%) There was a similar trend in Generic's Q2 numbers as we saw in Q1, where...

Kolmannen osapuolen analyysi

Generic: Prioritising growth over margins - ABG

22% organic sales growth y-o-y Lower than expected gross margin Price increases should help gross margin in Q2 Q1: Sales growth of 22%, EBIT margin of 16.3% (21.3%) Generic's Q1 numbers were quite eventful as there was a new strategic direction prioritising...

Kolmannen osapuolen analyysi

Generic: 2024 outlook still looks solid - ABG

12% organic sales growth y-o-y Opex increase and IAC affect Q4 Profitability assumptions down on slightly higher opex Q4: Sales growth of 12%, adj. EBIT margin of 19% (21.5%) Generic reported Q4 numbers were slightly behind our expectations. Net sales...

Kolmannen osapuolen analyysi

Generic: Solid Q3, softer outlook for '24e - ABG

15% organic sales growth y-o-y Inera volumes slightly delayed Minimal changes to long-term estimates Q3: Sales growth of 15%, EBIT margin of 22.6% (22.2%) Generic reported solid Q3 numbers with net sales of SEK 34.7m (+15% y-o-y, all organic), as the...

Kolmannen osapuolen analyysi

Generic: Inera deal sets up exciting 2024 - ABG

We expect a solid Q3 with 12% organic sales growth 15% EBIT growth y-o-y in Q3e Inera framework agreement behind our revisions Q3e: gradual recovery to continue Generic has historically showed a stable development that stems from a recurring SaaS offering...

Kolmannen osapuolen analyysi

Generic: Impressive profitability in Q2 - ABG

Solid sales growth at 10.4% y-o-y, all organic EBIT growth of 28% with excellent cost control Demand is holding up well into H2 Q2: Sales growth of 10.4%, EBIT margin of 20% (17.2%) Generic reported a solid quarter with net sales of SEK 34.6m (+10.4%...